Analysis of hospital registry data presented at the American Stroke Association's International Stroke Conference 2026 reveals that patients who suffered a brain bleed while on multiple antiplatelet medications or stronger agents faced higher odds of dying in the hospital compared to those not taking any antiplatelet drugs. The study, which examined data from over 426,000 adults hospitalized for intracranial hemorrhage between 2011 and 2021, found that aspirin alone did not increase mortality risk and was linked to better outcomes.
Antiplatelet medications, such as aspirin, clopidogrel, prasugrel, and ticagrelor, are commonly prescribed to prevent blood clots in patients with heart disease or ischemic stroke. However, their impact on outcomes after a brain bleed has been unclear. Lead author Santosh Murthy, M.D., M.P.H., from Weill Cornell Medicine, noted that prior research grouped all antiplatelet therapies together, masking potential differences. This study, using data from the American Heart Association's Get With The Guidelines-Stroke Registry, aimed to differentiate risks.
Among the 426,481 patients, 109,512 were on a single antiplatelet, 17,009 were on dual therapy, and 300,558 were not on any antiplatelet. After adjusting for demographics, comorbidities, stroke severity, and hospital characteristics, the researchers found that patients taking aspirin alone had no increased risk of in-hospital death and even showed lower odds of an unfavorable outcome (death or discharge to hospice). In contrast, those on stronger antiplatelet agents, alone or with aspirin, had a significantly higher risk of death. The trend toward worse outcomes with stronger or dual therapy persisted but did not reach statistical significance for the composite unfavorable outcome.
American Stroke Association volunteer expert Jonathan Rosand, M.D., M.Sc., FAHA, emphasized that while dual antiplatelet therapy benefits many patients with coronary artery disease, it carries risks. "If a stroke occurs while on these treatments, it is more likely to be fatal," he said. "Patients should check with their healthcare professional to ensure the medications are still appropriate." Rosand, a professor at Harvard and founder of the Global Brain Care Coalition, was not involved in the study.
Murthy cautioned that the findings do not imply patients should avoid antiplatelet therapy when prescribed. Instead, they highlight the need for tailored management after a brain bleed. Current guidelines recommend discontinuing antiplatelets immediately after a bleed and do not routinely recommend platelet transfusions unless surgery is needed. Future research should explore whether platelet transfusions improve outcomes differently based on the type and number of antiplatelet medications.
The study is limited by its retrospective design and lack of data on bleed characteristics like location and volume. Intracranial hemorrhage accounts for about 10% of all strokes in the U.S., according to the American Heart Association's 2026 Heart Disease and Stroke Statistics. The findings are considered preliminary until published in a peer-reviewed journal.
